108 results match your criteria: "The London Breast Institute[Affiliation]"
Anticancer Res
April 2009
The London Breast Institute, The Princess Grace Hospitals, London, W1M 3FD, UK.
There is a large and compelling body of epidemiological and experimental evidence that oestrogens are the fuel behind the aetiology of breast cancer. The carcinogenic effects of oestrogen are postulated to be mediated by: the stimulation of cellular proliferation through their receptor-mediated hormonal activity. Other mechanisms include; direct genotoxic effects by increasing mutation rates through a cytochrome P450-mediated metabolic activation and induction of aneuploidy.
View Article and Find Full Text PDFCancer Genomics Proteomics
April 2009
The London Breast Institute, The Princess Grace Hospital, London, UK.
Background: The post-translational modification of proteins, including glycosylation, is known to differ between normal and tumour cells. In this study, the expression profile of two glycosyltranferases, UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase-6 (ppGalNAc-T6) and alpha6-sialyl-transferase-I (ST6GalNAc-I) was assessed, in a cohort of women with breast cancer.
Patients And Methods: Breast cancer tissues (n=127) and normal background tissues (n=33) were collected immediately after excision during surgery.
Anticancer Res
February 2009
The London Breast Institute, The Princess Grace Hospital, London, UK.
Background: Osteopontin (OPN) overexpression in breast cancer has been associated with adverse pathological and clinical outcomes. In this study, the OPN expression profiles were examined in a cohort of breast cancer patients.
Patients And Methods: RNA extraction and reverse transcription were performed on breast carcinomas (n = 127) and normal tissues (n = 33).
Surg Oncol
March 2010
The London Breast Institute, The Princess Grace Hospital, 45 Nottingham Place, London W1U 5NY, UK.
Introduction: HER-2 over-expression is implicated in the pathogenesis of breast cancer and represents a key marker and determinant of patient outcome. Trastuzumab/Herceptin (TZ) is a recombinant humanised monoclonal antibody which targets HER-2. Introduction into clinical practice has significantly improved the natural history of HER-2 over-expressing tumors and has altered the standard of care for these women.
View Article and Find Full Text PDFBreast Cancer Res Treat
April 2009
The London Breast Institute, The Princess Grace Hospital, 45 Nottingham Place, London W1U 5NY, UK.
Introduction: The advent of sentinel lymph node biopsy (SLNB) and improvements in histopathological and molecular analysis have increased the rate at which micrometastases (MM) are identified. However, their significance has been the subject of much debate. In this article we review the literature concerning axillary lymph node (ALN) MM, with particular reference to SLNB.
View Article and Find Full Text PDFInt J Clin Pract
March 2008
The London Breast Institute, The Princess Grace Hospital, London, UK.
Introduction & Background: Contrast-enhanced magnetic resonance imaging (MRI) of the breast has been recently introduced as a potential clinical tool for the detection, diagnosis, staging and management of breast cancer. In this article, we consider the established and evolving roles of MRI with particular reference to screening in high risk women and staging of the primary tumour. Controversies are discussed in the context of the tumour biology and natural history of breast cancer.
View Article and Find Full Text PDFSurg Oncol
August 2008
The London Breast Institute, The Princess Grace Hospital, London, UK.
Introduction: The management of early breast cancer with skin-sparing mastectomy (SSM) and immediate breast reconstruction (IBR) is not based on evidence from randomised controlled trials. The purpose of this study is to evaluate the oncological safety, post-operative morbidity and patients' satisfaction with SSM and IBR using the latissimus dorsi (LD) myocutaneous flap and/or breast prosthesis.
Methods: Eighty-three consecutive women underwent 93 SSMs with IBR (10 bilateral), using the LD flap plus implant (n=55) or implant alone (n=38), indications included early breast cancer and prophylaxis due to BRCA-1 gene mutation.
Breast Cancer Res Treat
September 2008
The London Breast Institute, The Princess Grace Hospital, 45 Nottingham Place, London, W1U 5NY, UK.
Ductal carcinoma in-situ (DCIS) is a heterogeneous disease, in terms of its radiological characteristics, histological morphology and molecular attributes. This diversity is reflected in its natural history and influences optimal treatment strategy. A significant proportion of DCIS lesions behave in a clinically benign fashion and do not progress to invasive disease.
View Article and Find Full Text PDF